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A major subset of human cancers is associated with
CD8+ T cell infiltration yet tumor rejection fails due to
the dominant effects of multiple immune inhibitory
mechanisms. These include expression of the inhibitory
receptors CTLA-4 and PD-1 by T cells and expression
of the tryptophan-catabolizing enzyme indoleamine-2,3-
dioxygenase (IDO) within the tumor microenvironment.
It has been anticipated, therefore, that combined block-
ade of two or more inhibitory pathways may be neces-
sary for maximal therapeutic benefit. Using the B16.SIY
transplantable tumor model, we found that administra-
tion of doublets of aCTLA-4, aPD-L1 or an IDOi led to
strikingly effective immune-mediated tumor control in
vivo. We examined whether the potent therapeutic effect
of these combinations might be attributed to increased
priming versus restored function of T cells within the
tumor microenvironment. Analysis of SIY-specific T cell
responses in the tumor-draining lymph node or spleen
early following therapy revealed only a minimal elevation
with the doublets. However, within the tumor-microen-
vironment, each of the effective combinations was asso-
ciated with markedly augmented proliferation and IL-2
production by tumor-infiltrating CD8+ T cells. No major
depletion of Tregs was detected in the tumor site. In
order to assess whether this increased function of tumor-
infiltrating lymphocytes (TILs) was intrinsic to those cells
or required new T cell entry, the S1P inhibitor FTY720
was utilized. Administration of FTY720 resulted in near
total loss of circulating T cells. However, the restoration
of IL-2 production and proliferation of CD8+ TILs was
still observed. At later times points, after tumor rejection
was proceeding, increased frequencies of SIY-specific
T cells were observed in the circulation. aCTLA-4 plus
aPD-L1 treatment also resulted in significant tumor con-
trol in the BrafV600E/PTEN-/- genetic tumor model.
Our results suggest that combinatorial immunotherapies
with potent synergy share the property of augmenting IL-
2 production and proliferation by TILs directly within the
tumor. These are attractive combination therapies for
clinical translation, and examination of TIL proliferation
should be pursued as a pharmacodynamic biomarker in
the clinic.
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